Corrigendum to ‘Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial’: [Journal of Thrombosis and Haemostasis Volume 22, Issue 6, June 2024, Pages 1704-1714] (Journal of Thrombosis and Haemostasis (2024) 22(6) (1704–1714), (S1538783624001697), (10.1016/j.jtha.2024.03.011))

EVE trial investigators

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret the omission of author Micah J Mooberry from the original author list. This has now been corrected as above. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)756
Number of pages1
JournalJournal of Thrombosis and Haemostasis
Volume23
Issue number2
DOIs
StatePublished - Feb 2025

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial’: [Journal of Thrombosis and Haemostasis Volume 22, Issue 6, June 2024, Pages 1704-1714] (Journal of Thrombosis and Haemostasis (2024) 22(6) (1704–1714), (S1538783624001697), (10.1016/j.jtha.2024.03.011))'. Together they form a unique fingerprint.

Cite this